• Something wrong with this record ?

Preliminary evaluation of a new prototype interferon-gamma release assay for the detection of Mycobacterium tuberculosis-specific T-cell responses in patients with tuberculosis

M. Ibrahimová, K. Doležalová, L. Bača, M. Sukholytka, E. Grage-Griebenow, D. Zapf, S. Saschenbrecker, V. Herbst, E. Kopecká, MK. Vašáková

. 2025 ; 70 (2) : 493-503. [pub] 20250303

Language English Country Czech Republic

Document type Journal Article, Evaluation Study

Persistent link   https://www.medvik.cz/link/bmc25013005

Screening for tuberculosis infections (TBI) using the tuberculin skin test or interferon-gamma release assays (IGRA) is crucial in controlling the global TB burden. This study evaluates the performance of a new IGRA for the detection of T-cell responses against Mycobacterium tuberculosis. Blood samples from 34 adults with tuberculosis disease (TB) and from 30 children with TB, TBI or without TB were analyzed using the prototype Quan-T-Cell TB (EUROIMMUN). The pediatric samples were additionally measured using the established QuantiFERON-TB Gold Plus assay (Qiagen). Clinical performance and inter-assay concordance were analyzed. The prototype Quan-T-Cell TB yielded positivity rates of 88.2% and 100% in adults with TB and children with TBI, respectively, at a specificity of 93.8%. Comparison between the two IGRAs showed positive, negative and overall agreement rates of 100%, 93.8% and 96.3%, respectively, with a kappa score of 0.924 indicating almost perfect agreement. Our study shows promising results of the new prototype Quan-T-Cell TB, as reflected by high concordance with the final diagnosis in adults and children and performance comparable to that of the QuantiFERON IGRA. In individual cases, the data suggest that the prototype Quan-T-Cell TB may be even more consistent with TBI-related clinical findings. Unlike the QuantiFERON assay, the Quan-T-Cell TB has a predefined borderline range, which is advantageous as it may help to differentiate non-specific variation near the cut-off, and fewer sample tubes are required per analysis. The new Quan-T-Cell TB may therefore be a good alternative to the established QuantiFERON IGRA for TBI screening. Further assay optimization is underway, including evaluation studies based on larger patient and control cohorts.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25013005
003      
CZ-PrNML
005      
20250605092904.0
007      
ta
008      
250605s2025 xr f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12223-025-01252-w $2 doi
035    __
$a (PubMed)40032785
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Ibrahimová, Markéta $u Laboratory of Immunology, Thomayer University Hospital, Prague, Czech Republic $1 https://orcid.org/0009000759714349
245    10
$a Preliminary evaluation of a new prototype interferon-gamma release assay for the detection of Mycobacterium tuberculosis-specific T-cell responses in patients with tuberculosis / $c M. Ibrahimová, K. Doležalová, L. Bača, M. Sukholytka, E. Grage-Griebenow, D. Zapf, S. Saschenbrecker, V. Herbst, E. Kopecká, MK. Vašáková
520    9_
$a Screening for tuberculosis infections (TBI) using the tuberculin skin test or interferon-gamma release assays (IGRA) is crucial in controlling the global TB burden. This study evaluates the performance of a new IGRA for the detection of T-cell responses against Mycobacterium tuberculosis. Blood samples from 34 adults with tuberculosis disease (TB) and from 30 children with TB, TBI or without TB were analyzed using the prototype Quan-T-Cell TB (EUROIMMUN). The pediatric samples were additionally measured using the established QuantiFERON-TB Gold Plus assay (Qiagen). Clinical performance and inter-assay concordance were analyzed. The prototype Quan-T-Cell TB yielded positivity rates of 88.2% and 100% in adults with TB and children with TBI, respectively, at a specificity of 93.8%. Comparison between the two IGRAs showed positive, negative and overall agreement rates of 100%, 93.8% and 96.3%, respectively, with a kappa score of 0.924 indicating almost perfect agreement. Our study shows promising results of the new prototype Quan-T-Cell TB, as reflected by high concordance with the final diagnosis in adults and children and performance comparable to that of the QuantiFERON IGRA. In individual cases, the data suggest that the prototype Quan-T-Cell TB may be even more consistent with TBI-related clinical findings. Unlike the QuantiFERON assay, the Quan-T-Cell TB has a predefined borderline range, which is advantageous as it may help to differentiate non-specific variation near the cut-off, and fewer sample tubes are required per analysis. The new Quan-T-Cell TB may therefore be a good alternative to the established QuantiFERON IGRA for TBI screening. Further assay optimization is underway, including evaluation studies based on larger patient and control cohorts.
650    _2
$a lidé $7 D006801
650    12
$a test pomocí interferonu gama $x metody $7 D059425
650    12
$a Mycobacterium tuberculosis $x imunologie $7 D009169
650    _2
$a dospělí $7 D000328
650    _2
$a dítě $7 D002648
650    12
$a tuberkulóza $x diagnóza $x imunologie $x mikrobiologie $7 D014376
650    12
$a T-lymfocyty $x imunologie $7 D013601
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a předškolní dítě $7 D002675
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a mladiství $7 D000293
650    _2
$a mladý dospělý $7 D055815
650    _2
$a interferon gama $7 D007371
650    _2
$a senioři $7 D000368
650    _2
$a kojenec $7 D007223
655    _2
$a časopisecké články $7 D016428
655    _2
$a hodnotící studie $7 D023362
700    1_
$a Doležalová, Karolína $u Department of Pediatrics, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Bača, Luboš $u Department of Pediatrics, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Sukholytka, Mariia $u Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Grage-Griebenow, Evelin $u Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany
700    1_
$a Zapf, Dorinja $u Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany
700    1_
$a Saschenbrecker, Sandra $u Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany. s.saschenbrecker@euroimmun.de $1 https://orcid.org/000000024769915X
700    1_
$a Herbst, Victor $u Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany
700    1_
$a Kopecká, Emilia $u Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Vašáková, Martina Koziar $u Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
773    0_
$w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 70, č. 2 (2025), s. 493-503
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40032785 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250605 $b ABA008
991    __
$a 20250605092857 $b ABA008
999    __
$a ok $b bmc $g 2333582 $s 1250115
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 70 $c 2 $d 493-503 $e 20250303 $i 1874-9356 $m Folia microbiologica $n Folia Microbiol (Praha) $x MED00011005
LZP    __
$a Pubmed-20250605

Find record

Citation metrics

Archiving options